Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells $30,471.14 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $18.29, for a total transaction of $30,471.14. Following the transaction, the director now owns 118,043 shares in the company, valued at approximately $2,159,006.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Denali Therapeutics Price Performance

Denali Therapeutics stock traded down $0.52 during midday trading on Wednesday, reaching $16.82. The stock had a trading volume of 1,367,429 shares, compared to its average volume of 1,156,004. The firm’s fifty day simple moving average is $19.27 and its two-hundred day simple moving average is $19.29. Denali Therapeutics Inc. has a twelve month low of $15.45 and a twelve month high of $33.31. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of -15.70 and a beta of 1.33.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.05). Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same quarter last year, the business posted ($0.75) earnings per share. As a group, sell-side analysts predict that Denali Therapeutics Inc. will post -2.62 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on DNLI. UBS Group lowered their price objective on shares of Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, April 9th. The Goldman Sachs Group decreased their price target on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. Wedbush restated an “outperform” rating and issued a $31.00 price target on shares of Denali Therapeutics in a research report on Wednesday, February 28th. Finally, HC Wainwright decreased their price target on shares of Denali Therapeutics from $105.00 to $95.00 and set a “buy” rating on the stock in a research report on Wednesday, February 28th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $41.22.

Hedge Funds Weigh In On Denali Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC boosted its stake in shares of Denali Therapeutics by 216.7% during the 4th quarter. CWM LLC now owns 2,011 shares of the company’s stock valued at $43,000 after buying an additional 1,376 shares during the period. Assetmark Inc. boosted its stake in shares of Denali Therapeutics by 49.1% during the 3rd quarter. Assetmark Inc. now owns 2,148 shares of the company’s stock valued at $44,000 after buying an additional 707 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Denali Therapeutics by 85.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,669 shares of the company’s stock valued at $46,000 after buying an additional 768 shares during the period. KBC Group NV acquired a new stake in shares of Denali Therapeutics during the 4th quarter valued at $53,000. Finally, Fisher Asset Management LLC acquired a new stake in shares of Denali Therapeutics during the 4th quarter valued at $59,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.